Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

Acquired resistance to antiangiogenic drugs, such as sorafenib, is a major clinical problem. We studied development of a resistance to sorafenib in new preclinical models of human hepatocellular carcinoma (HCC) along with a strategy to delay such resistance—combination with metronomic chemotherapy....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Terence C. Tang, Shan Man, Ping Xu, Giulio Francia, Kae Hashimoto, Urban Emmenegger, Robert S. Kerbel
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2010-11-01
Edice:	Neoplasia: An International Journal for Oncology Research
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1476558610800417
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!